Acrivon Therapeutics, Inc. Common Stock (ACRV) — Defensive Interval Ratio
Acrivon Therapeutics, Inc. Common Stock (ACRV) has a Defensive Interval Ratio of 2300 days as of September 2025. Defensive assets of $93.85 Million (cash $-, short-term investments $93.85 Million, receivables $-) cover 2300 days of daily cash needs of $40.80K/day. See Acrivon Therapeutics, Inc. Common Stock (ACRV) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
Acrivon Therapeutics, Inc. Common Stock Defensive Interval Ratio (2021–2024)
This chart shows how Acrivon Therapeutics, Inc. Common Stock's Defensive Interval Ratio has evolved across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at 2300 days, meaning defensive assets of $93.85 Million can fund 2300 days of operations without new revenue. See ACRV net asset quality score to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for Acrivon Therapeutics, Inc. Common Stock (2021–2024)
The table below presents the year-by-year Defensive Interval Ratio for Acrivon Therapeutics, Inc. Common Stock from 2021 to 2024, covering 4 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Acrivon Therapeutics, Inc. Common Stock (ACRV) market capitalisation.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2024 | 2961 days | $139.66 Million | $47.16K/day | $- | $139.66 Million | ▲ +452 days |
| 2023 | 2509 days | $91.44 Million | $36.45K/day | $- | $91.44 Million | ▼ -2994 days |
| 2022 | 5503 days | $98.23 Million | $17.85K/day | $- | $98.23 Million | ▲ +5503 days |
| 2021 | 0 days | $0.00 | $7.98K/day | $- | $0.00 | — |